Zura Bio (NASDAQ:ZURA) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report published on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a research note on Thursday, September 19th.

Zura Bio Stock Down 0.9 %

NASDAQ ZURA opened at $4.60 on Monday. The company has a 50-day simple moving average of $4.04 and a 200-day simple moving average of $4.00. Zura Bio has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, equities analysts anticipate that Zura Bio will post -0.47 earnings per share for the current year.

Insider Transactions at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the sale, the director now directly owns 2,085,418 shares of the company’s stock, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 15.80% of the company’s stock.

Institutional Trading of Zura Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in shares of Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after purchasing an additional 6,412 shares in the last quarter. Forefront Analytics LLC raised its holdings in shares of Zura Bio by 22.1% in the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after purchasing an additional 7,531 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Zura Bio in the 2nd quarter worth approximately $43,000. Finally, SG Americas Securities LLC bought a new stake in shares of Zura Bio in the 3rd quarter worth approximately $62,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.